Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. - Donovan-Banfield I; Penrice-Randal R; Goldswain H; Rzeszutek AM; Pilgrim J; Bullock K; Saunders G; Northey J; Dong X; Ryan Y; Reynolds H; Tetlow M; et al. (Nature communications, 2022)